6 results on '"Hokkanen, Laura"'
Search Results
2. Brain magnetic resonance imaging findings six months after critical COVID-19: A prospective cohort study.
- Author
-
Ollila H, Pihlajamaa J, Martola J, Kuusela L, Blennow K, Zetterberg H, Salmela V, Hokkanen L, Tiainen M, and Hästbacka J
- Subjects
- Humans, Infant, Newborn, Prospective Studies, Magnetic Resonance Imaging adverse effects, Risk Factors, Brain, Oxygen, Cerebral Hemorrhage complications, COVID-19 complications
- Abstract
Background: COVID-19 patients suffered from neurological symptoms in the acute phase. Whether this led to long-term consequences was unknown. We studied long-term brain MRI findings in ICU-treated COVID-19 patients and compared them with findings in groups with less severe acute disease., Materials and Methods: In this prospective cohort study, 69 ICU-treated, 46 ward-treated, and 46 home-isolated patients, as well as 53 non-COVID-19 controls, underwent brain MRI six months after acute COVID-19. Plasma neurofilament light chain (NfL), a biomarker of neuroaxonal injury, was measured simultaneously., Results: Ischaemic infarctions existed in 5.8% of ICU-treated patients. Cerebral microbleeds (CMBs) existed in 27 (39.1%) ICU-treated, 13 (28.3%) ward-treated, 8 (17.4%) home-isolated COVID-19 patients, and 12 (22.6%) non-COVID controls. Patients with CMBs were older (p < 0.001), had a higher level of plasma NfL (p = 0.003), and higher supplementary oxygen days (p < 0.001). In multivariable analysis, age (OR 1.06, 95% CI 1.02-1.09) and supplementary oxygen days (OR 1.07, 95% CI 1.02-1.13) were associated with CMBs. The ICU group showed prevalent distribution of CMBs in deep regions., Conclusion: Age and supplementary oxygen days were independently associated with CMBs; COVID-19 status showed no association. Accumulation of risk factors in the ICU group may explain the higher prevalence of CMBs., Trial Registration: ClinicalTrials.govNCT04864938, registered February 9, 2021., Competing Interests: Declaration of Competing Interest H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). K.B. has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. On behalf of all the other authors, the corresponding author states that there is no conflict of interest., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
3. Health-related quality of life after surviving intensive care for COVID-19: a prospective multicenter cohort study.
- Author
-
Halvorsen P, Hultström M, Hästbacka J, Larsson IM, Eklund R, Arnberg FK, Hokkanen L, Frithiof R, Wallin E, Orwelius L, and Lipcsey M
- Subjects
- Humans, Male, Female, Middle Aged, Quality of Life, Cohort Studies, Prospective Studies, Critical Care psychology, Intensive Care Units, Pain, COVID-19 therapy, Hypertension
- Abstract
In survivors of severe coronavirus disease 2019 (COVID-19) incomplete mental and physical recovery may considerably impact daily activities and health-related quality of life (HRQoL). HRQoL can be evaluated with the RAND-36 questionnaire, a multidimensional instrument that assesses physical and mental aspects of health in eight dimensions. The objective was to investigate HRQoL in intensive care patients previously treated for COVID-19 at three Nordic university hospitals, in a prospective multi-center cohort study. HRQoL was measured using RAND-36, 3-9 months after discharge from intensive care units (ICU). One hospital performed a second follow-up 12 months after discharge. A score under the lower limit of the 95% confidence interval in the reference cohorts was considered as significantly reduced HRQoL. We screened 542 and included 252 patients. There was more than twice as many male (174) as female (78) patients and the median age was 61 (interquartile range, IQR 52-69) years. Hypertension was the most common comorbidity observed in 132 (52%) patients and 121 (48%) patients were mechanically ventilated for a median of 8 (IQR 4-14) days. In RAND-36 physical functioning, physical role functioning, general health (p < 0.001 for all) and social functioning (p < 0.05) were below reference, whereas bodily pain, emotional role functioning and mental health were not. In a time-to-event analysis female sex was associated with a decreased chance of reaching the reference HRQoL in the physical function, bodily pain and mental health dimensions. Higher body mass index was found in the physical functioning dimension and hypertension in the physical functioning, vitality and social functioning dimensions. Similar results were seen for diabetes mellitus in general health, vitality and mental health dimensions, as well as pulmonary illness in the physical role functioning dimension and psychiatric diagnosis in the social functioning dimension. Mechanical ventilation was associated with a decreased likelihood of achieving reference HRQoL in the bodily pain and physical functioning dimensions. Patients treated in an ICU because of COVID-19 had lower HRQoL 3-9 months after ICU discharge than 95% of the general population. Physical dimensions were more severely affected than mental dimensions. Female sex and several comorbidities were associated with a slower rate of recovery.Study registration: clinicaltrials.gov: NCT04316884 registered on the 13th of March 2020, NCT04474249 registered on the 29th of June 2020 and NCT04864938 registered on the 4th of April 2021., (© 2023. Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
4. Long-term cognitive functioning is impaired in ICU-treated COVID-19 patients: a comprehensive controlled neuropsychological study.
- Author
-
Ollila H, Pihlaja R, Koskinen S, Tuulio-Henriksson A, Salmela V, Tiainen M, Hokkanen L, and Hästbacka J
- Subjects
- Cognition, Cohort Studies, Humans, Intensive Care Units, Male, Prospective Studies, COVID-19, Cognitive Dysfunction epidemiology, Cognitive Dysfunction etiology
- Abstract
Background: Cognitive impairment has emerged as a common post-acute sequela of coronavirus disease 2019 (COVID-19). We hypothesised that cognitive impairment exists in patients after COVID-19 and that it is most severe in patients admitted to the intensive care unit (ICU)., Methods: This prospective controlled cohort study of 213 participants performed at the Helsinki University Hospital and the University of Helsinki, Finland, comprised three groups of patients-ICU-treated (n = 72), ward-treated (n = 49), and home-isolated (n = 44)-with confirmed COVID-19 between March 13 and December 31, 2020, participating in a comprehensive neuropsychological evaluation six months after the acute phase. Our study included a control group with no history of COVID-19 (n = 48). Medical and demographic data were collected from electronic patient records and interviews carried out four months after the acute phase. Questionnaires filled six months after the acute phase provided information about change in cognitive functioning observed by a close informant, as well as the presence of self-reported depressive and post-traumatic symptoms., Results: The groups differed (effect size η
2 p = 0.065, p = 0.004) in the total cognitive score, calculated from neuropsychological measures in three domains (attention, executive functions, and memory). Both ICU-treated (p = 0.011) and ward-treated patients (p = 0.005) performed worse than home-isolated patients. Among those with more than 12 years of education, ICU-treated patients performed worse in the attention domain than ward-treated patients (p = 0.021) or non-COVID controls (p = 0.045); ICU-treated male patients, in particular, were impaired in executive functions (p = 0.037)., Conclusions: ICU-treated COVID-19 patients, compared to patients with less severe acute COVID-19 or non-COVID controls, showed more severe long-term cognitive impairment. Among those with more than 12 years of education, impairment existed particularly in the domains of attention and for men, of executive functions., Trial Registration Number: ClinicalTrials.gov NCT04864938, retrospectively registered February 9, 2021., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
5. APOE ε4 associates with increased risk of severe COVID-19, cerebral microhaemorrhages and post-COVID mental fatigue: a Finnish biobank, autopsy and clinical study.
- Author
-
Kurki SN, Kantonen J, Kaivola K, Hokkanen L, Mäyränpää MI, Puttonen H, Martola J, Pöyhönen M, Kero M, Tuimala J, Carpén O, Kantele A, Vapalahti O, Tiainen M, Tienari PJ, Kaila K, Hästbacka J, and Myllykangas L
- Subjects
- Adult, Aged, Autopsy, Biological Specimen Banks, COVID-19 diagnosis, COVID-19 epidemiology, Cerebral Hemorrhage diagnosis, Cerebral Hemorrhage epidemiology, Cohort Studies, Female, Finland epidemiology, Genetic Association Studies methods, Heterozygote, Humans, Male, Mental Fatigue diagnosis, Mental Fatigue epidemiology, Microvessels pathology, Middle Aged, Prospective Studies, Risk Factors, Young Adult, Post-Acute COVID-19 Syndrome, Apolipoprotein E4 genetics, COVID-19 complications, COVID-19 genetics, Cerebral Hemorrhage genetics, Mental Fatigue genetics, Patient Acuity
- Abstract
Apolipoprotein E ε4 allele (APOE4) has been shown to associate with increased susceptibility to SARS-CoV-2 infection and COVID-19 mortality in some previous genetic studies, but information on the role of APOE4 on the underlying pathology and parallel clinical manifestations is scarce. Here we studied the genetic association between APOE and COVID-19 in Finnish biobank, autopsy and prospective clinical cohort datasets. In line with previous work, our data on 2611 cases showed that APOE4 carriership associates with severe COVID-19 in intensive care patients compared with non-infected population controls after matching for age, sex and cardiovascular disease status. Histopathological examination of brain autopsy material of 21 COVID-19 cases provided evidence that perivascular microhaemorrhages are more prevalent in APOE4 carriers. Finally, our analysis of post-COVID fatigue in a prospective clinical cohort of 156 subjects revealed that APOE4 carriership independently associates with higher mental fatigue compared to non-carriers at six months after initial illness. In conclusion, the present data on Finns suggests that APOE4 is a risk factor for severe COVID-19 and post-COVID mental fatigue and provides the first indication that some of this effect could be mediated via increased cerebrovascular damage. Further studies in larger cohorts and animal models are warranted., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
6. APOE ε4 associates with increased risk of severe COVID-19, cerebral microhaemorrhages and post-COVID mental fatigue: a Finnish biobank, autopsy and clinical study
- Author
-
FinnGen, Kurki, Samu N., Kantonen, Jonas, Kaivola, Karri, Hokkanen, Laura, Mäyranpää, Mikko I., Puttonen, Henri, Martola, Juha, Pöyhönen, Minna, Kero, Mia, Tuimala, Jarno, Carpen, Olli, Kantele, Anu, Vapalahti, Olli, Tiainen, Marjaana, Tienari, Pentti J., Kaila, Kai, Hastbacka, Johanna, Myllykangas, Liisa, Molecular and Integrative Biosciences Research Programme, HUSLAB, Faculty of Biological and Environmental Sciences, Department of Psychology and Logopedics, Behavioural Sciences, Department of Pathology, HUS Medical Imaging Center, Department of Medical and Clinical Genetics, Minna Pöyhönen / Principal Investigator, Olli Mikael Carpen / Principal Investigator, Precision Cancer Pathology, Department of Medicine, Department of Virology, Veterinary Biosciences, Veterinary Microbiology and Epidemiology, Helsinki One Health (HOH), Viral Zoonosis Research Unit, Olli Pekka Vapalahti / Principal Investigator, HUS Neurocenter, Clinicum, Department of Neurosciences, Neuroscience Center, Kai Kaila / Principal Investigator, Laboratory of Neurobiology, and HUS Perioperative, Intensive Care and Pain Medicine
- Subjects
Adult ,Male ,Heterozygote ,APOE4 ,Post-viral fatigue ,515 Psychology ,Apolipoprotein E4 ,COVID-19 sequelae ,DISEASE ,Pathology and Forensic Medicine ,Cohort Studies ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,Young Adult ,0302 clinical medicine ,Post-Acute COVID-19 Syndrome ,030502 gerontology ,Neuropsychology ,Risk Factors ,Humans ,Prospective Studies ,RC346-429 ,Finland ,Genetic Association Studies ,Neuropathology ,Aged ,Biological Specimen Banks ,Cerebral Hemorrhage ,Biobank ,SARS-CoV-2 ,Research ,3112 Neurosciences ,Patient Acuity ,COVID-19 ,Middle Aged ,Mental Fatigue ,Brain microhaemorrhage ,3. Good health ,Microvessels ,lipids (amino acids, peptides, and proteins) ,Female ,Neurology. Diseases of the nervous system ,Neurology (clinical) ,Autopsy ,0305 other medical science ,030217 neurology & neurosurgery ,APOE - Abstract
Apolipoprotein E ε4 allele (APOE4) has been shown to associate with increased susceptibility to SARS-CoV-2 infection and COVID-19 mortality in some previous genetic studies, but information on the role of APOE4 on the underlying pathology and parallel clinical manifestations is scarce. Here we studied the genetic association between APOE and COVID-19 in Finnish biobank, autopsy and prospective clinical cohort datasets. In line with previous work, our data on 2611 cases showed that APOE4 carriership associates with severe COVID-19 in intensive care patients compared with non-infected population controls after matching for age, sex and cardiovascular disease status. Histopathological examination of brain autopsy material of 21 COVID-19 cases provided evidence that perivascular microhaemorrhages are more prevalent in APOE4 carriers. Finally, our analysis of post-COVID fatigue in a prospective clinical cohort of 156 subjects revealed that APOE4 carriership independently associates with higher mental fatigue compared to non-carriers at six months after initial illness. In conclusion, the present data on Finns suggests that APOE4 is a risk factor for severe COVID-19 and post-COVID mental fatigue and provides the first indication that some of this effect could be mediated via increased cerebrovascular damage. Further studies in larger cohorts and animal models are warranted.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.